PharmaFocus Today – Page 2 – media

Hengrui is about to acquire the “first domestic

Chinese pharmaceutical companies represented by Hengrui Medicine and Ipomoea australis are actively planning the clinical development of URAT1 inhibitors. With the acceleration of the research process, a new generation of highly effective and low-toxic gout treatment drugs is expected to be quickly launched on the market, promoting innovation in the field of gout treatment. Significant clinical need Hyperuricemia is a metabolic syndrome caused by purine metabolism disorder. Its clinical diagnosis requires that the blood uric acid level of an adult exceeds 420μmol/L (7mg/dl) twice on different days. Gout is a crystal-related arthropathy. As a common metabolic rheumatic disease, its pathological basis is hyperuricemia – abnormal purine metabolism or reduced uric acid excretion causes increased blood uric acid, which in turn leads to the deposition of monosodium urate crystals. The current treatment of chronic hyperuricemia and gout mainly revolves around two core mechanisms: inhibiting uric acid synthesis and promoting uric acid ...
- Source: drugdu
- 52
- June 4, 2025
Antibiotic-Resistant Gonorrhoea Cases Rise in England

The UK Health Security Agency (UKHSA) has published the latest figures on sexually transmitted infections (STIs) in England. They show an ongoing increase in cases of antibiotic-resistant gonorrhoea, despite a general decline in gonorrhoea infections. The figures showed a 16% reduction in gonorrhoea diagnoses generally, with 71,802 cases recorded in 2024 compared with 85,370 in 2023. The agency described this as encouraging and noted that the decline was most pronounced among young people aged 15-24 years, with diagnoses falling by more than a third (36%). Antibiotic Resistance a Growing Concern Despite the overall decline, the UKHSA warned of a “concerning acceleration” in cases of antibiotic-resistant gonorrhoea. While most infections remain treatable, resistance to ceftriaxone — the first-line treatment — poses significant clinical challenges. Ceftriaxone resistance remains uncommon in the UK but is frequently reported in the Asia-Pacific region. The UKHSA noted that many of the resistant cases had links ...
- Source: drugdu
- 43
- June 4, 2025
How Can A Daily Cup Of Beans Improve Your Health?

By Dennis Thompson HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) — Beans aren’t just the musical fruit, they can be pure magic for your health, a new study says. Eating a daily cup of beans significantly improved the health of a small group of people with prediabetes – a condition in which elevated blood sugar levels have nearly caused type 2 diabetes. “Our study found that bean consumption helped significantly lower cholesterol and reduce inflammation in people with prediabetes, although glucose levels were not changed,” researcher Morganne Smith, a doctoral candidate at the Illinois Institute of Technology, said in a news release. This is good news, as people with prediabetes often have high cholesterol and chronic inflammation, both of which increase their risk of other chronic health problems like heart disease, Smith said. For the study, researchers randomly assigned 72 people to eat black beans, chickpeas or rice for ...
- Source: drugdu
- 41
- June 4, 2025
Innovative Ecological Synergy Resonance, Revenue Growth Breaks Record

In 2024, under the policy of “innovative drugs” being written into the government work report for the first time, the number of innovative drug management lines and asset quality of China’s biomedical market will continue to break through, and become an important pole of the global pharmaceutical market, opening the prelude to the global competition of local innovative drugs. In this milestone year, the multinational pharmaceutical company Astellas, which has been in China for 30 years, has also ushered in a crucial turning point. The appointment of the first local “leader” Zhao Ping injects new development momentum into the enterprise – internal cultural transformation and upgrading, continuous improvement of external influence and reputation, and acceleration of localization strategy Furthermore, for the first time, Astellai has included enhancing the capabilities of its Chinese team as a key focus of the group. It has achieved multiple accomplishments in China, including continuous approval ...
- Source: drugdu
- 49
- June 3, 2025
BioNTech acquired drugs from a Chinese company for less than $1 billion and resold them for over $10 billion

Last year, German biotechnology company BioNTech spent less than $1 billion to acquire a Chinese company’s investigational cancer drug, which was sold for over $11 billion in just six months. According to public statements from both companies, BMS will collaborate with BioNTech to develop and commercialize a tumor drug called BNT327, which is a bispecific antibody drug targeting PD-L1 and VEGF-A for the treatment of various solid tumors. BNT327 was acquired by BioNTech last year through the acquisition of Chinese biotechnology company Pumis Biotech. Last November, BioNTech acquired Pumis Biotech for only $800 million, and with the subsequent milestone payment of $150 million, the entire acquisition transaction was less than $1 billion. BioNTech has thus acquired full global ownership of BNT327. Currently, BNT327 is undergoing clinical trials as a first-line treatment for extensive stage small cell lung cancer and non-small cell lung cancer. So far, over 1000 patients have received ...
- Source: drugdu
- 54
- June 3, 2025
Inside the Battle to Stop the Outbreak

For 30 years, pediatrician Tammy Camp, MD, of Lubbock, Texas, never once encountered a case of measles on the job. Now, that’s all changed. As she told colleagues last week, that’s not all that’s different in West Texas, the epicenter of the 2025 measles outbreak in the Southwest. “We’re seeing mothers who are scared, crying in the clinic because they have a baby that they have delivered just 6 weeks ago and they know that the child is too young to receive a measles vaccine,” she said in a National Academy of Medicine update about the outbreak. “Yet, they know they need to return to work because they are responsible for putting food on the table for the rest of their family members.” To make matters more complicated, Camp has to worry about disease transmission in her clinic. While Lubbock is 90 miles from the outbreak’s rural ground zero ...
- Source: drugdu
- 45
- June 3, 2025
FDA Approves Tryptyr Eye Drops for Dry Eye Disease

By Stephanie Brown HealthDay ReporterMONDAY, June 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease. Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly increase natural tear production. The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day. Approval of Tryptyr was based on the results of two phase 3 clinical trials (COMET-2 and COMET-3). More than 930 patients with a history of dry eye disease were randomly assigned (1:1) to Tryptyr or vehicle. As early as day 1, Tryptyr delivered statistically significant natural tear production. Patients taking Tryptyr (versus vehicle) experienced a ≥10-mm increase in ...
- Source: drugdu
- 40
- June 3, 2025
Alphamab Oncology Presents New Progress in Clinical Research of JSKN003

June 3, Alphamab Oncology Pharmaceuticals (09966) announced that it recently presented the latest research results of JSKN003 at the 2025 ASCO Annual Meeting. The study conducted a summary analysis of the efficacy and safety of multiple indications, mainly including a Phase I clinical study in patients with advanced/metastatic solid tumors, involving different doses of JSKN003. As of February 28, 2025, a total of 46 PROC patients participated in the study. Among them, 91.3% of patients had tumor shrinkage, the objective response rate (ORR) was 63.0%, the median progression-free survival (mPFS) was 7.7 months, and the 9-month overall survival rate (OS) was 89.9%. In HER2 IHC 0 patients, the ORR was 52.4%, and in HER2 IHC 1+, 2+, and 3+ patients, the ORR was 72.2%. In terms of safety, 19.6% of patients experienced grade 3 or 4 treatment-related adverse events (TRAEs), but no deaths caused by TRAEs occurred. In addition, the ...
- Source: drugdu
- 41
- June 3, 2025
Application for marketing authorization of ranibizumab injection accepted

Huadong Medicine(000963) announced on June 3 that the marketing authorization application for ranibizumab injection (R&D code HJY28) submitted by the company’s wholly-owned subsidiary Hangzhou Sino-US East China Pharmaceutical Co., Ltd. was accepted. Ranibizumab injection is indicated in adults for the treatment of wet (neovascular) age-related macular degeneration (AMD), the treatment of visual impairment caused by diabetic macular edema (DME), the treatment of diabetic retinopathy (DR) [proliferative diabetic retinopathy (PDR) and moderate to severe non-proliferative diabetic retinopathy (NPDR)], the treatment of visual impairment caused by macular edema secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)), and the treatment of visual impairment caused by choroidal neovascularization (CNV, i.e. CNV secondary to pathological myopia (PM) and other causes). Ranibizumab injection is indicated for premature infants for the treatment of retinopathy of prematurity (ROP) in zone I (stage 1+, 2+, 3 or 3+), zone II ...
- Source: drugdu
- 43
- June 3, 2025
Insomnia creates a multi-billion dollar market

Recently, Lemborexant, a dual orexin receptor antagonist originally developed by Eisai, was approved for marketing by the National Medical Products Administration, marking the official entry of China’s insomnia treatment field into the “dual orexin antagonist era.” Global sales exceeded 2.6 billion yuan Unlike traditional sedative hypnotic drugs, Lebrexan competitively binds to orexin type 1 receptor (OX1R) and type 2 receptor (OX2R), precisely inhibiting orexin-mediated wakefulness drive, thereby inducing natural sleep. In addition, unlike traditional GABA-A hypnotic drugs that inhibit rapid eye movement sleep (REM), Lebrexan can simultaneously extend the duration of non-rapid eye movement sleep (NREM) and REM, optimizing sleep structure to make it closer to the physiological sleep state. Clinical trials have shown that Lebrexan has a mild effect on patients’ memory and cognitive function, and does not significantly interfere with daytime activities (especially driving and other behaviors that require mental concentration). Studies have shown that the drug has ...
- Source: drugdu
- 41
- June 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.